EP Patent

EP3760637A3 — Stable solid forms of regadenoson

Assigned to Curia Italy SRL · Expires 2021-04-07 · 5y expired

What this patent protects

A process for the preparation of the amorphous form of Regadenoson of formulais disclosed together with new crystalline polymorphic forms E and F and methods for their preparation. Regadenoson amorphous form can be prepared in mild reaction conditions with high chemical purity (&…

USPTO Abstract

A process for the preparation of the amorphous form of Regadenoson of formulais disclosed together with new crystalline polymorphic forms E and F and methods for their preparation. Regadenoson amorphous form can be prepared in mild reaction conditions with high chemical purity (>99.6%) and high stability to the heating.

Drugs covered by this patent

Patent Metadata

Patent number
EP3760637A3
Jurisdiction
EP
Classification
—
Expires
2021-04-07
Drug substance claim
No
Drug product claim
No
Assignee
Curia Italy SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.